Evidence map›Paper›PMID 37786905›Full record

ReviewIbrain2021

Aberrant TDP-43 phosphorylation: a key wind gap from TDP-43 to TDP-43 proteinopathy.

Zi-Qi Huang, Zhi-Sheng Ba, Nan-Qu Huang, Yuan-Yuan Li, Yong Luo

Open access · bronzeAbstract readReview
In one paragraph

Review in Ibrain, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Zi-Qi HuangDepartment of Neurology Third Affiliated Hospital of Zunyi Medical University & First People's Hospital of Zunyi Zunyi Guizhou China.
Zhi-Sheng BaDrug Clinical Trial Institution, Third Affiliated Hospital of Zunyi Medical University & First People's Hospital of Zunyi Zunyi Guizhou China.
Nan-Qu HuangDrug Clinical Trial Institution, Third Affiliated Hospital of Zunyi Medical University & First People's Hospital of Zunyi Zunyi Guizhou China.
Yuan-Yuan LiDrug Clinical Trial Institution, Third Affiliated Hospital of Zunyi Medical University & First People's Hospital of Zunyi Zunyi Guizhou China.
Yong LuoDepartment of Neurology Third Affiliated Hospital of Zunyi Medical University & First People's Hospital of Zunyi Zunyi Guizhou China.
Zunyi Medical University · CNFirst People’s Hospital of Zunyi · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

TDP-43 proteinopathy is a kind of neurodegenerative diseases related to the TAR DNA-binding protein of 43-kDa molecular weight (TDP-43). The typical neurodegenerative diseases include amyotrophic lateral sclerosis (ALS), frontotemporal lobar degeneration (FTLD), Alzheimer's disease (AD), Parkinson's disease (PD) and so on. As the disease process cannot be blocked or slowed down, these patients have poor quality of life and poor prognosis, and bring a huge burden to the family and society. So far, the specific pathogenesis of TDP-43 proteinopathy is not clear, and there is no effective preventive measure and treatment program for this kind of disease. TDP-43 plays an important role in triggering or promoting the occurrence and progression of TDP-43 proteinopathy. The hyperphosphorylation of TDP-43 is undoubtedly an important factor in triggering or promoting the process of TDP-43 proteinopathy. Hyperphosphorylation of TDP-43 can inhibit the degradation of TDP-43, aggravate the aggregation of TDP-43 protein, increase the wrong localization of TDP-43 in cells, and enhance the cytotoxicity of TDP-43. More and more evidences show that the hyperphosphorylation of TDP-43 plays an important role in the pathogenesis of TDP-43 proteinopathy. Inhibition of TDP-43 hyperphosphorylation may be one of the important strategies for the treatment of TDP-43 proteinopathy. Therefore, this article reviews the role of TDP-43 phosphorylation in TDP-43 proteinopathy and the related mechanisms.

Indexed as

Aberrant TDP‐43 phosphorylationNeurodegenerative diseasesReviewTAR DNA‐binding protein of 43‐kDa molecular weightTDP‐43 proteinopathy

Identifiers

PMID37786905
PMCPMC10528777
OpenAlexW4205110535

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.